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SUMMARY
Historical and laboratory data from the first two hundred twenty-nine patients
who were evaluated in the Renal Stone Clinic at the Yale-New Haven Medical Center
were analyzed according to type of renal calculus, in an attempt to examine various
risk factors leading to the development of the specific type of stone. Three patients
had

cystine

stones!

six

patients

had

uric

acid

stones!

nine

patients

formed

magnesium ammonium phosphate stones! seventeen formed calcium phosphate stones!
and two hundred one formed calcium oxalate or mixed calcium stones. The major focus
of this analysis was on the identification of preventable risk factors in patients
with the garden-variety calcium oxalate stone.

One or more risk factors were

identified in the vast majority of these patients, and several novel aspects of
certain risk factors were discovered.

INTRODUCTION
Renal stone disease is a medical condition of far more than academic interest.
Occurring in approximately three per cent of the American population, renal stones
account for one in every 1000 hospital admissions in the United States.
1981)

(Broadus,

The colic that renal calculi can cause is said to be "one of the more severe,

frightening pains encountered in medical practice." (Walker, 1980)

Because of the

growing body of data implying that nephrolithiasis is often preventable, great effort
has been expended in the characterization of the disease and the habits that may
cause the disease. Although the growing body of knowledge is continually expanding,
many of the treatment modalities for nephrolithiasis have not kept up with the grow¬
ing knowledge base. For that reason this study was designed to examine the records
of the first 229 patients at the Yale-New Haven Medical Center Renal Stone Clinic to
complete a metabolic screening evaluation for underlying causes of nephrolithiasis.
Renal stone disease, in essence, is a constellation of several entities. In gener¬
al the term "nephrolithiasis" refers to calculi primarily composed of cystine, magnes¬
ium ammonium phosphate, uric acid, calcium phosphate, calcium oxalate, or mixed
calcium oxalate-calcium phosphate. (Mixed calcium oxalate-calcium phosphate stones
refer to those calculi which are mostly composed of calcium oxalate, but have a cal¬
cium phosphate composition greater than twenty per cent.)

As will be seen, the

crystallographic stone type forms a rational basis by which to subdivide patients
with renal stone disease, and the following schema will provide the organizational
format for this thesis:
I.
II.
III.
IV.
V.

Cystine Stones
Uric Acid Stones
Magnesium Ammonium Phosphate Stones
Calcium Phosphate Stones
Calcium Oxalate and Mixed Calcium Stones
A.
Calculi as a secondary manifestation of other illnesses
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B.

Calculi as a primary disease—"garden-variety" stones

Several points regarding this schema are noteworthy at this juncture. Although
this thesis will concentrate mostly on calcium oxalate stones, it will review the other
stone types and make a clear distinction between calcium phosphate and calcium ox¬
alate stones, a distinction often not made in the existing literature on the subject.
The category of calcium oxalate stones and mixed calcium stones will be considered
in two parts. As secondary manifestations of other illnesses (only a small portion of
the total are in this category), their underlying pathophysiology will be reviewed. For
calcium oxalate and mixed calcium stones forming without a known primary illness,
the risk factor concept will be introduced, highlighting the risk factors of family his¬
tory,

hypouresis,

hypercalciuria,

and

hyperuricosuria.

Although

treatment

and

outcome are beyond the scope of this study, the risk factor approach to renal stone
disease allows the hope that elimination of some or all of the statistical risk factors
may, in fact, prevent or significantly lower the subsequent incidence of renal stone
formation in this patient population.

Cystine Stones
Cystine is the least soluble of all of the naturally occurring amino acids. In nor¬
mal urine its maximum solubility is approximately 300 mg/L. These stones are formed
only by homozygous cystinurics whose genetic defect in renal tubular amino acid re¬
absorption causes them to excrete 600 to 1400 mg of cystine daily.

With the urine

being oversaturated with cystine, spontaneous formation of cystine crystals will
take place, contributing to the formation of cystine stones.

An alkaline urine can

increase the solubility of cystine, but disorders of urine acidification alone are not
responsible for cystine stone formation.
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Because the intestinal transport system for cystine is either absent or defec¬
tive in almost all patients with cystinuria, the cystine that is excreted in the urine
must be derived endogenously from the hepatic metabolism of dietary methionine.
Because the transport system is missing in the renal tubules, likewise, cystine reab¬
sorption does not take place and cystinuria results.
Any patient with a history of recurrent renal calculi is a potential cystine stone
former.

A diagnosis may be suggested by an early age of onset of stone disease.

Definitive

diagnosis

is

made

by

stone

analysis,

demonstration

of

cystine

crystalluria, or by quantitative urinary amino acid analysis.
This study will reinforce the statement that hypercystinuria is associated with
formation of cystine stones and indicate its rarity within a renal stone clinic
population.

Uric Acid Stones
Uric acid stones are usually pure, affect mostly middle-age males, and account
for approximately five per cent of stone disease in Western countries.

As the final

breakdown product of purine metabolism in humans, uric acid production and excretion
are affected by dietary purines as well as endogenous purine production. Because the
rate of metabolism of endogenous purines in a given individual remains constant un¬
der normal circumstances, variation in uric acid production is largely a function of
dietary purine intake.
of proximal
sorption.

tubular

Uric acid is excreted into the urine through a complex system
reabsorption,

tubular

secretion,

and

post-secretory

reab¬

Tubular reabsorption is the dominant quantitative process governing the

amount of uric acid excreted.
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Whether the urine uric acid will precipitate to form a stone is largely a function
of the ambient urinary pH.

An acidified urine will tend to shift the equilibrium be¬

tween uric acid and its urate salt in the direction of the acid form. Uric acid is far
less soluble than its urate salt. Because the pK

of uric acid is 5.75—in the center

of the physiological range for urine pH—the relative concentrations of uric acid and
urate salts are exquisitely sensitive to urine pH. For example, given a urine uric acid
excretion of 1000 mg per day at a pH of 6.0, the amount of free uric acid present
would be 360 mg. But at a pH of 5.0, the amount of free uric acid present would be 350
mg. Since the ultimate solubility of uric acid in urine is about 100 mg/L at pH of 5.0,
and 1500 mg/L at pH of 7.0, the shift in pH by one could be the difference between
precipitation and solubility for uric acid.
Diagnosis is best made through laboratory analysis of a stone.

Because uric

acid stones are radiolucent, they can only be suspected from an intravenous pyelogram.

This study will support the concepts that hyperuricosuria and hypouresis

should be considered as physical chemical risk factors associated with uric acid
stones.

Magnesium Ammonium Phosphate Stones
Magnesium ammonium phosphate stones (MAP) stones are a relatively rare but
extremely morbid type of renal calculi.

As with cystine and uric acid stones, MAP

stone formation is a logical consequence of physical chemistry. MAP stones are com¬
posed of struvite (MgNH^PO^eH^Q) admixed with small amounts of carbonate-apatite
(Ca^(PO^)gCO^.).

In sterile urine, the solubility product of struvite is never ex¬

ceeded, and MAP stones do not form. The pathological presence of urease-producing
bacteria can cause an alkaline urine and increased concentrations of ammonium, car-
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bonate, and relatively insoluble, multiply charged phosphate ions.

These charges

oversaturate the urine with respect to both magnesium ammonium phosphate and car¬
bonate-apatite, quickly leading to struvite stone formation.

Urease acts on urea in

the following sequence:
Urea (CO(NH.L) + H.O ====Urease====> 2 NH
L.

L.

+ CO.
O

L.

L-

2 NH3 + 2 H20 <========> 2 NH4+ + 2 OH~
C0o + H O <========> H CO <========> H+ + HCO ~
2
2
2
3
3
H+ + HCO./ + 2 OH" <========> CO~2 + 2 H O
u*

W

With some ninety per cent of clinical isolates of Proteus, Staphyloccus aureus, and
Bacteroides species producing urease and some thirty per cent of Klebsiella and
Pseudomonas acting in the same manner, all of these bacterial strains have been
clinically implicated in series of MAP stone patients. Proteus species, however, have
been the most common isolate.
The basic prerequisite for a MAP stone is an abnormality that predisposes to
urinary tract infection.

These derangements include megaureter, ureteral reflux or

obstruction, ileal conduits, nephrostomy drainage, medullary sponge kidney, neuro¬
genic bladder, or the presence of any non-MAP stone.

Diagnosis is made thorugh

radiologic visualization of a staghorn calculus or by crystallographic analysis of
stone material. This study confirms previous reports that in a substantial proportion
of MAP stone patients urine colony counts of urease-producing bacteria were less
than 100,000 per milliliter. (Broadus, 1981). It reveals, however, a lower incidence of
associated abnormalities associated with non-MAP stone formation than reported by
others. (Smith, 1976)

Calcium Phosphate Stones
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Unlike some conventional considerations of nephrolithiasis, this study empha¬
sizes that

calcium phosphate stones (a relatively rare phenomenon) sthould be

considered as distinct from the common calcium oxalate stone. (Coe, 1973, Coe, 1974,
Ullmann, 1982).
An essential feature of calcium phosphate stones is that they form in a sterile
alkaline urine.

The importance of the urine pH is rarely appreciated. With the con¬

centration of HPO^ ^ rising rapidly in the presence of increasing pH, the components
of a calcium phosphate stone reach concentrations of supersaturation, and ultimate¬
ly oversaturation, which forces calculus formation. (Broadus, 1981, Nordin, 1973).
Since, as this study confirms, calcium phosphate stones only form in a sterile alka¬
line urine, their presence suggests an underlying mechanism associated

with a

persistently alkaline urine.
A normal kidney maintains the pH of the extracellular fulids by entirely reclaim¬
ing the filtered load of bicarbonate and by excreting a quantity of fixed acid equal
to that produced endogenously.
in the proximal tubule.

Almost all of the filtered bicarbonate is reabsorbed

The distal tubule operates to remove remaining bicarbonate

and set the final urinary pH. The normal kidney can achieve a final urinary pH of 5.0
or lower. (Brenner, 1980)
One acidification disorder seen in calcium phosphate stone patients is complete
distal renal tubular acidosis (RTA). Patients with this illness are rarely able to pro¬
duce a urine with a pH of less than 5.5.

RTA can be caused by genetic factors,

Sjogren's syndrome, medullary sponge kidney, Ehlers-Danlos syndrome, amphotericin,
obstructive uropathy, and several other miscellaneous conditions. (Kathpalia, 1980)
The resulting acidosis inhibits citrate production in the renal cortex, leading to
a reduced citrate excretion rate.

Because the citrate can then have less of an ef-
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fect on binding urinary calcium into soluble complexes, RTA acts as a double-edged
sword to cause calcium phosphate stone crystallization.

RTA may also stimulate hy-

percalciuria by causing a defect in distal tubule calcium reabsoprtion or through
mobilization of bone calcium, as bone minerals are used to buffer serum acids. Incom¬
plete distal RTA, in which there is no systemic acidosis although the urine is
alkaline, might also lead to calcium phosphate stone formation, but this question was
not evaluated in detail in the present study. (Broadus, 1981)
Medications may also predispose a patient to form calcium phosphate calculi.
(Parfitt, 1969) As a carbonic anhydrase inhibitor, acetazolamide will inhibit proximal
tubular bicarbonate reabsorption, simultaneously inhibit citrate production, decrease
the

excretion

of

ammonium

ion

and

titratable

acid,

and

increase

the

urine

alkalinity—in effect causing secondary or "exogenous" RTA. Chronic low-dose inges¬
tion of calcium or sodium bicarbonate antacids may

cause urine alkalinity and

calcium phosphate stones as well. (Broadus, 1981)
Diagnosis can be made only through crystallographic analysis.

Calcium Oxalate and Mixed Calcium Stones
Stones containing calcium oxalate make up the lion's share of the stones.

This

category was defined as including patients who met at least one of the following cri¬
teria: 1) crystallographic analysis of a renal calculus which showed that the stone
was composed of at least fifty per cent calcium oxalate, and/or 2) radiologic examin¬
ation showing the presence of a radioopaque stone (or stones) in a patient with no
suggestive evidence of another stone type.

Of the 179 patients in this group, 156

(87%) satisfied the first definition. Predominantly males are afflicted with this stone
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type. (Johnson, 1979) The risk factor concept may be applied most fruitfully to this
population.
A short review of the physical chemistry associated with the formation of
calcium oxalate-containing is in order. The underlying concept to be addressed is the
equilibrium between the solid crystal and dissolved ionic phases of a solute such as
calcium oxalate. In an "undersaturated" system, the addition of solid phase material
to the system leads to the complete dissolution of the solid material. When sufficient
solid phase material is added, however, the system becomes "saturated."

In this

condition, added solid phase material can only partially be dissolved into its ionic
components. If one removes the solid from this system, one is left with a "saturated"
solution of ions dissolved in water.

When sufficient quantities of a concentrated

solution of any of the solute components are added to the "saturated" solution, then
the

"saturated"

solution

will

become

"oversaturated,"

and

solid

crystals

will

spontaneously nucleate (i.e. precipitate) out. Although the case of calcium oxalate in
urine is a far more complex system than that in water (involving numerous soluble
components and ion-ion interactions) the aqueous system may be seen as a model for
precipitation of calcium oxalate crystals in urine.

When sufficient quantities of a

concentrated solution of any of the solute components (e.g., a hypercalciuric urine in
the distal renal collecting tubules is added to a "saturated" urine in the renal
collecting ducts), oversaturation may occur and calcium oxalate stone formation may
occur.

Because calcium oxalate is less soluble in normal urine than either calcium

phosphate,

uric

acid,

magnesium

ammonium

phosphate,

and

cystine,

sensitive to abnormal urinary perturbations than any other stone type.

it

is

more

This fact

likely accounts for the great frequency of calcium oxalate stone disease observed
among patients with nephrolithiasis (Broadus, 1981).

This fact also underlies the
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clinical utility of the risk factor concept in practice, some of these risk factors
including

abnormalities

which

have

no

direct

influence

on

calcium

or

oxalate

metabolism per se.
To facilitate consideration of this stone type,

the following etiologic and

epidemiologic schema will be followed:
I.

II.

Calcium Oxalate Stones Secondary to Established Primary Illnesses
A. Primary Hyperparathyroidism
B. Enteric Hyperoxaluria
C. Renal Tubular Acidosis
D. Sarcoidosis
E. Others: Vitamin D Excess, Immobilization, Uncontrolled Diabetes
Diabetes Mellitus, Glucocorticoid Excess, Thyrotoxicosis
Primary Risk Factors for Garden-Variety Calcium Oxalate Stones
A. Family History
B. Hyperoxaluria
C. Inadequate Urine Volume
D. Hyperuricosuria
E. "Idiopathic” Hypercalciuria
1.
"Absorptive" Hypercalciuria
2.
"Renal" Hypercalciuria
3.
"Dietary" Hypercalciuria
F. Multiple Risk Factors

Brief consideration will be given to the primary diseases producing secondary
nephrolitihiasisj these made up only a small portion of a calcium oxalate stone popu¬
lation.

The garden-variety stone—lacking a known primary etiology—will then be

considered separately. Based primarily on the physical chemical properties described
above, individual risk factors will be considered—much in the manner for which such
variables as cigarette smoking, serum cholesterol, and hypertension are commonly
evaluated in the case of coronary artery disease.

Etiologies of "idiopathic" hyper¬

calciuria will receive particular attention, with emphasis placed upon the importance
of "absorptive" hypercalciuria and the newly-defined entity "dietary" hypercalciuria.
Primary Hyperparathyroidism
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Although there will be little of novel interest to say regarding primary hyperpa¬
rathyroidism, a number of basic points will be reemphasized.
portant primary disorder of renal stone disease.

This disorder is an im¬

Indeed, some fifty per cent of

hyperparathyroid patients have renal calculi as their presenting complaint. (Broadus,
1981) The key point meriting emphasis is that certain patients with primary hyperpa¬
rathyroidism manifest disproportionate hypercalciuria vis-^-vis the fasting serum
calcium concentration, and it is this subpopulation which is predominantly at risk for
stones.

The principal pathophysiological correlate explaining the disproportionate

hypercalciuria

is

the

circulatory

concentration

of

1,25-(OH)^D,

so

that

the

hypercalciuria is predominantly "absorptive" in nature. (Broadus, 1980, 1981)
Enteric Hyperoxaluria
Enteric hyperoxaluria has been considered as a distinct entity since 1972, fol¬
lowing recognition that hyperoxaluria and a predisposition to nephrolithiasis were
seen in a variety of gastrointestinal disorders, including Crohn's disease, nontropical sprue, chronic pancreatitis and biliary tract disease, blind loop syndrome, and
following ileal resection or jejunoileal bypass, but not including ulcerative colitis.
This study will echo the association between enteric hyperoxaluria and renal calculi,
but will not explore this relatively minor cause of stone disease further. The patho¬
physiology is thought to involve a colonic hyperabsorption of dietary oxalate.
particular mechanism of this hyperabsorption has not been established.

The

By predis¬

posing the urine to oversaturation, enteric hyperoxaluria is thought to stimulate
calcium oxalate stone formation. (Smith, 1980)
Renal Tubular Acidosis
These

stones

are

significantly

considered in a previous section.

composed

of

calcium

phosphate

and

were

14-

-

Sarcoidosis
Hypercalciuria has been noted in approximately forty per cent of patients with
sarcoidosis, and this disease has been associated with calcium oxalate stone forma¬
tion. (Winnacker, 1963, Broadus, 1981)

The hypercalciuria is a function of dietary

calcium intake, renal function, bone resorption, and abnormal rates of conversion of
25-OH D to l^S-COHi^D. (Papoulos, 1979) By promoting an oversaturated urine with
respect to calcium, sarcoidosis can predispose to calcium oxalate stone formation.
Diagnosis of sarcoidosis is made from radiographic, chemical, and biopsy evidence of
the disease.

This study will confirm that this disease is infrequently seen in a stone

population. (Broadus, 1931)
Other Secondary Hypercalciurias
Other primary diseases have been suggested as predisposing patients to hyper¬
calciuria and, rarely, nephrolithiasis, although they were not observed in this series.
(Broadus, 1931)

These diseases include "excess Vitamin D intake," immobilization,

rapidly progressive osteoporosis, malignant osteolysis, medullary sponge kidney, un¬
controlled diabetes mellitus, glucocorticoid excess, thyrotoxicosis, acromegaly, and
furosemide administration.

All have been variously associated with hypercalciuria,

but their relationship to stone formation has been poorly studied.
Family History
Family history is strongly associated with this disease. No genetic markers have
yet been identified, but family history confers a definite statistical risk. (Resnick,
1963) This study confirms the high rate of positive family history for renal stones
among patients with renal stones.
Hyperoxaluria
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As described in the section on physical chemistry, hyperoxaluria, theoretically,
would predispose a patient to formation of calcium oxalate stones.

Because urine

oxalate was only studied systematically in patients suspected of having enteric
hyperoxaluria, and not in the entire stone population, this study did not determine
whether hyperoxaluria was a significant risk factor in patients with garden variety
calcium oxalate stone disease.
Hypouresis
As calcium oxalate in normal urine just borders on the edge of oversaturation,
hypouresis is yet another risk factor that can play a critical role in pathogenesis.
An inadequate urine output might be sufficient cause for calcium oxalate becoming
oversaturated in urine, compelling calcium oxalate crystal formation. (Pak, 1980) The
common prevalence of inadequate fluid intake and resulting low urinary output in
Israeli settlement towns of the 1950's was, indeed, suggested as the cause of the
high incidence of renal stone disease in that country. (Frank, 1959)

In the present

study, an "inadequate" urine was considered to be less than one liter per day.
Hyperuricosuria
A risk factor that will be emphasized is hyperuricosuria. The entity of hyperuricosuric calcium oxalate nephrolithiasis was initially recognized in the 1970's. (Coe,
1973, Coe, Kidney International, 1978, Coe, Nephrolithiasis, 1978). A reliable mecha¬
nism for this process has not yet been established, although there have been reports
that epitaxy might play a role.

According to this theory, when different crystals

types share a similar lattice structure, saturation with one solute type might induce
heterogeneous nucleation (i.e. precipitation) and/or crystal growth of another type
of solute. Since calcium oxalate, uric acid, and monosodium urate crystals have been
reported to share similar lattice structures, this might be the mechanism by which
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hyperuricosuria favors production of calcium oxalate stones. (Lonsdale, 1968)
tails of purine metabolism were considered earlier under Uric Acid Stones.

De¬
What

makes assessing this risk factor especially difficult is that statistically precise
limits for normal uric acid excretion have not been established.
absorption of purines is not

regulated,

hyperuricosuria

Because intestinal

is frequently

a

simple

function of purine intake. This study employed the upper normal limit recommended by
others, even though it was recognized that these limits were not statistically based.
These criteria defined hyperuricosuria as uric acid excretion of more than 800 mg per
day in males and 750 mg per day in females. (Coe, Kidney International, 1978).

Three

potential mechanisms for hyperuricosuria in patients with oxalate stone disease are:
1) endogenous uric acid overproduction, 2) purine gluttony, and 3) increased frac¬
tional excretion of uric acid. (Broadus, 1978) This study will echo that little support
for the third hypothesis exists.

That a majority of patients with hyperuricosuria are

normouricemic suggests that two subpopulations might exist, one of overproducers,
the other of purine gluttons.

Clearly, exogenous purines would influence uric acid

excretion in both subpopulations, and the line between them is thin.

17-

-

"Idiopathic" Hypercalciuria
The risk factor to which particular attention will be paid is hypercalciuria.

An

association between hypercalciuria and calcium stone formation has been known
since 1939. (Flocks, 1939) Unfortunately, delineating the nature of the hypercalciuria
has progressed slowly. Since 1958, the renal stone literature has contended with the
term "idiopathic hypercalciuria" to describe those hypercalciuric patients for whom
no primary disease could readily be identified as causing their hypercalciuria.

These

patients were thought to have normocalcemic hypercalciuria and a tendency to hypo¬
phosphatemia.

They were noted to have increased intestinal calcium absorption,

which, at the time, was considered secondary to a "renal leak" of calcium. (Henneman,
1958) In the ensuing quarter-century, debate has raged over the mechanisms and fre¬
quencies of subgroups of "absorptive," "resorptive," and "renal" hypercalciurias that
were thought to comprise the idiopathic hypercalciurias. (Broadus, 1934).This study
will emphasize the prevalence of the entity known as "absorptive hypercalciuria."
In practice "hypercalciuria" is difficult to define in a meaningful way because
there are so many dietary influences on calcium excretion.

On a "free" or undefined

diet, calcium excretion can be increased by dietary protein, sodium, and carbohyd¬
rate, and decreased by dietary oxalate and phosphorus.

Dietary calcium itself can

profoundly increase urinary calcium, especially in renal stone formers. (Peacock,
1967, Lemann, 1979)
A "hypercalciuric" patient was defined in this study as one who met at least one
of the following criteria: On either or both of the protocol diets (see Appendix Two),
they had 1) a calcium excretion rate of greater than 250 mg per day in females; 2)
greater than 300 mg per day in males; or 3) greater than 4 mg per kg per day in either
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sex. These limits are consistent with those recommended by most investigators within
the United States. (Broadus, 1931)
The most common subtype of idiopathic hypercalciuria associated with the “typi¬
cal oxalate

stone" is absorptive hypercalciuria.

As currently

understood, this

disease involves increased circulating levels of IjZS-COHi^D, leading to intestinal
hyperabsorption of calcium. These patients have an increased gut absorption of cal¬
cium that presents the normal kidney with an increased load of calcium, which is then
excreted,

causing

hypercalciuria.

(Coe,

Nephrolithiasis,

1978,

Broadus,

1981,

Broadus, 1984) This study examined one proposed mechanism for absorptive hypercal¬
ciuria, involving a primary renal tubular phosphate leak. (Lemann, 1980) According to
theory, for which this study found no support, the phosphate leak leads to a reduc¬
tion in TmP/GFR and serum phosphate concentrations and secondary increases in
IjZS-tOHl^D and intestinal calcium absorption.

A full discussion of the phosphate

leak hypothesis is beyond the scope of this thesis.
Renal hypercalciuria is thought to involve a primary defect in renal tubular cal¬
cium reabsorption.

The tubular calcium losses lead to secondary hyperparathyroid¬

ism, the theory goes, stimulating 1,25-(OH).7D production, calcium absorption, and
reducing TmP/GFR and serum phosphorous. (Broadus, 1979, Broadus, 1981). This study
found no evidence of such a mechanism.
Patients with so-called "idiopathic" hypercalciuria have been noted to increase
their urine excretion of calcium markedly in response to increasing dietary calcium
from a low-normal to a high-normal level. In contrast, normal subjects show a minimal
increase under these conditions. (Broadus, 1979) In this series, it was presumed that
hypercalciuric patients would manifest a greater degree of hypercalciuria on the
fixed (1000 mg) calcium diet than on the "free" diet sample (typically with 3 lower in-
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take of calcium).

As will be seen, a substantial minority of patients did not display

such a pattern. Rather, they displayed more marked hypercalciuria on the "free" diet
than on the fixed high-normal calcium diet, even though, on the average, the calcium
intake on the fixed diet was some one-third higher than that on the "free" diet. Most
of this subset of patients did not have an identifiable metabolic abnormality on de¬
tailed testing.

It follows that dietary factors other than calcium must have influ¬

enced the results for calcium excretion on the "free" diet, and the term "Dietary
Hypercalciuria" is introduced in connection with these patients. The patients consid¬
ered in this category were those who displayed hypercalciuria on one of the protocol
diets and whose calcium excretion was more than 50 mg/day higher on the "free" diet
as compared with the fixed 1000-mg calcium diet, along with those patients who, par¬
adoxically, were hypercalciuric on both diets, but whose performance on a calcium
tolerance test indicated that they did not have absorptive hypercalciuria.

Together

these two subgroups were considered as one cohort. Because such variables as diet¬
ary calcium, phosphorus, protein, and sodium are not set in the "free" diet, while they
are regulated in the fixed diet, the hypothesis that one or more of these dietary
factors might influence the result on the free diet urine calcium was considered.
Diagnosis of hypercalciuric etiologies was made through measurements of fast¬
ing calcium excretion, 24-hour calcium excretion, total serum calcium, ionized serum
calcium, serum immunoreactive PTH, nephrogenous cAMP, and total cAMP excretion,
as detailed in the methods sections below and in Appendix Two.

METHODS
The Stone Clinic: The Yale-New Haven Medical Center Renal Stone Clinic is a
weekly outpatient referral clinic in New Haven, Connecticut.

Since its inception in
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1977, the clinic has been conducted by a minimum of three internists, a nurse, and a
dietician.
The Patient Population: Although a small number of patients were self-referred
to the clinic, the vast majority were either referred by a urologist, a general practi¬
tioner, or an internist.

The clinic has been in continuous operation since 1977. This

study examines the historical record of the first 2clinic patients who had been
evaluated as of October 1982.
Screening Schedule: The evaluation screen at the stone clinic was established
to take place over two clinic visits. The purpose of the initial visit was to determine
all historical, radiological, and physical exam parameters relating to the patient's
stone disease, to obtain serum and urine specimens reflecting the "free" diet, and to
instruct the patient on the nature of the fixed diet, from which urine calcium was
quantified upon the second clinic visit. The purpose of the second clinic visit was to
inform the patient of the results of tests conducted on the first visit and to plan
future tests and/or therapy.

In the case of unexplained hypercalciuria,

involve scheduling a calcium tolerance test.

this would

If radiological information available at

the first visit was unsatisfactory, a set of KUB and oblique abdominal films was
scheduled for the second visit.

Therapy might commence with dietary counseling

and/or medication.
Initial Evaluation'. Prior to arrival at the clinic for his first appointment, each
patient was sent a copy of a "First Renal Stone Clinic Visit" form. (See Appendix Two)
Along with the form is sent a collapsible 24-hour urine container and instructions for
collecting a one-day sample. Each patient was instructed to arrive to the clinic in a
fasting state.

On admission to the clinic, a complete history and physical examina¬

tion was performed on each patient.

Particular attention was paid to the history of
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stone events, dietary, and associated factors as noted on the forms in Appendix Two.
When permission was granted to study a patient's family history, a detailed pedigree
was prepared for each first-degree relative of the affected patient.

Patients with

at least one first-degree relative with a reported history of passage of a renal cal¬
culus were considered as having a positive family history.

A detailed, quantitative,

dietary history was obtained by a trained nutritionist, using the diet history form in
Appendix Two. This history corresponded to the day of the "free" urine collection.
Radiological evaluation: An intravenous pyelogram (IVP) from within one year of
intake was examined on every patient, whenever possible.

Particular attention was

paid to assessing anatomical abnormalities predisposing to stone formation and de¬
termination of the quantity and quality of any stones present.
oblique

films

were

obtained

whenever

old

films

were

Flat abdominal and

insufficient

for

reliable

diagnosis of stone number, type, and/or location.
Laboratory evaluation: Results of previous stone analyses were examined and,
whenever possible, a representative recent stone was sent for crystallographic
analysis.

At the patient's inital clinic visit, fasting blood levels of calcium, phos¬

phorus, bicarbonate, chloride, creatinine, and uric acid were determined.

The inital

twenty-four hour urine specimen on a "free" or undefined diet (as noted on the diet
history form) was analyzed quantitatively for creatinine, calcium, sodium, phos¬
phorus, magnesium, uric acid, and TmP/GFR.
of uric acid was also determined.

In many cases the fractional excretion

Urine volumes were also noted and the creatinine

quantitated to ensure completeness of the collection.

A cle3n-catch, spot, fasting

urine was also obtained for culture and for pH determination by nitrazine paper or pH
meter. In all cases a cystine screen (nitroprusside) was performed on this specimen.
If the initial urinary pH was greater than 5.5, the patient was given nitrazine paper

for recording serial urinary pH values in order to document that the urine could be
acidified to a pH of less than 5.5.

The average pH of the first eighteen consecutive

urine samples was designated as the "mean pH." The presence and degree of hypercalciuria were evaluated by instructing patients to collect two twenty-four-hour ur¬
ine samples on a "fixed" or defined 1000—mg calcium diet.

For this regimen (see

patient form in Appendix Two) patients were instructed by the dietician to limit their
protein intake to approximately one gram per kg of body weight per day, to limit their
sodium intake to approximately one hundred milliequivalents per day, to eliminate
dairy products, and to supplement the diet with calcium gluconate tablets, two grams,
three times daily with meals.

The net calcium intake on the fixed diet was approxi¬

mately 1 gram per day, and the urine collections were obtained after at least one full
day on the diet. Patients who were hypercalciuric on either diet or both and for whom
no primary cause for the hypercalciuria was identified were then evaluated with an
"Oral Calcium Tolerance Test" described in Appendix Two. (Broadus, 1973) The calcemic response (in normal individuals it is usually less than 0.4 mg/dL) is an index of
calcium "tolerance." The calciuric response served as an index of intestinal calcium
absorption. Induced changes in nephrogenous cAMF' or total cAMP excretion served to
indicate parathyroid suppressibility, as it is the best clinical means of measuring
circulating parathyroid hormone activity. (Broadus, 1981) Absorptive hypercalciuria
was diagnosed in patients who met the strict criteria described in Appendix Two.
(Broadus, 1934).
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RESULTS
The stone population was made up of 163 males and 60 females.

This sex distri¬

bution was almost identical to that reported (70:30) in a previous study of a large
group of stone patients. (Prince, 1960) The mean age of the stone clinic patients at
the time of their first stone episode was 34 years. (See Figure One)

The mean fre¬

quency of previous stone episodes since the first stone episode among stone patients
was two per year. (See Figure Two) Two patients had sarcoidosis, three had cystinuria, four had renal tubular acidosis, eight had enteric hyperoxaluria, and ten had
primary hyperparathyroidism.

Of those patients without a known primary disease

explaining the formation of their calculi, six had uric acid stones, nine had magnes¬
ium ammonium phosphate stones, fifteen had calcium phosphate stones, and one
hundred eighty had calcium oxalate or mixed calcium stones. Eleven patients had more
than one type of stone.
Appendix One.

Detailed averages of urinary excretion rates appear in
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FIGURE 1:
Distribution of Ages At First Stone Episode
x-axis: age (years)...y-axis: number of patients
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FIGURE 2:
Frequency Distribution of Mean Annual Stone Episodes
x-axis: episodes per year...y-axis: percentage of patients
One patient's stone frequency fell above the range depicted on the table below.

26-

-

MAP Stones
Among the nine patients who dev/eloped MAP stones, three (33%) had a positive
family history for renal stone disease.

Although the organism count was higher in

this group (j-t=45,6Q0) than in the remainder of the stone patients studied (p.=9,9Q0,
S.D.=74,000, N=195), the difference was not large enough to be significant (p=.G74). A
positive culture was noted in six of the eight patients for whom a culture result was
available.

In this group of patients, 50% had a bacteriuria count of greater than

40,000 per milliliter, while only 6% of the remaining stone patients had bacteriuria
greater than 40,000 per milliliter.

Five of the eight patients with culture results

available had a colony count of less than one hundred thousand per milliliter. (See
Figures Three and Four)

Among the cases where a presumably causative organism

could be identified, Proteus mirabilis was the dominant organism in four cases,
Pseudomonas aeruginosa in one, and Enterococcus in one more.
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FIGURE 3:
Distribution of Organism Count in MAP Stone Patients
axis: organisms/ml...y-axis: number of patients whose colony count equalled the
value on the x-axis at the left side of the bar
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FIGURE 4:
Distribution of Organism Count in non-MAP Stone Patients
-axis: organisms/ml...y-axis: number of patients whose colony count equalled the
value on the x-axis at the left side of the bar
One patient's colony count was above the range depicted on the chart below.

29-

-

Among these nine patients, five had "urinary tract infection" as their primary
diagnosis predisposing them to renal calculus formation.

One had medullary sponge

kidney—presumably having an anatomical and functional urinary tract dysfunction
predisposing to urinary tract infection. One had hypouresis as a risk factor, as well
as a history of urinary tract infections (documented with repeated urinary cultures),
thought secondary to chronic nephrolithiasis.

One patient had a history of antacid

abuse and another was hyperuricosuric, both of which were thought to have induced a
"metabolic" stone formation and undocumented secondary urinary tract infection. The
TmP/GFR of the MAP stone population (M=2.4) was significantly less (p=.001) than
that observed in the remainder of the stone population (U=3.1, S.D.=0.7, N=194).
Uric Acid Stones
As a group, the uric acid stone population had a significantly (p=.003) lower ur¬
ine volume (M=10Q0 ml) than the rest of the

5ten€

patients (//=/£23 ml, S.D.=811,

N=223). Although 50% of this group had urine volumes less than 1000 ml, only 18% WO
of 223) of non-uric acid stone formers had such low urine volumes.

At this level of

urine output, hypouresis would be an appropriate term for describing their state.
Dietary purine intake per kg body weight (U=l .92 mg/kg, S.D.=1.09, N=S) was not
significantly different than that observed among the rest of the stone population
(p=l .70 mg/kg, S.D.=1.28, N=211).

Three of the six patients also had a history of

oxalate stones; two of the six had hyperuricosurial one had gout; and one had Crohn's
disease.

When compared to the rest of the stone population, the uric acid stone

formers had no significant difference (p>.05) in their serum or urinary uric acid
levels, or in their Fractional Excretion of Uric Acid.

The mean urinary pH measured

for two of the six patients with uric acid stones, was approximately the same as that
obtained in the non-uric acid stone population (p=5.8, S.D.=0.7, N=107). There were no
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known patients in this uric acid group who had any of the rare inborn error of
metabolism diseases that can cause uric acid stones.
Cystine Stones
All three of the patients who developed cystine stones in this series had a
diagnosis of cystinuria. Two of the patients (brothers) had a family history of stone
disease. The average age of onset of stone episodes was eighteen years. Daily urine
volumes averaged 1160 ml, and urine cystine averaged 311 rng/day.

All of the urine

cystine concentrations (p=648 mg/L) exceeded the maximum solubility (300 mg/L) of
cystine in urine.
Calcium Phosphate Stones
A total of seventeen patients formed pure or predominantly calcium phosphate
stones.

Two of these had renal tubular acidosis. Of the remaining fifteen patients

without a "primary" disease process leading to their formation of phosphate calculi,
two had a history of chronic antacid ingestion, and another had a history of regular
acetazolamide ingestion.

As such, there were a total of twelve patients without a

readily identifiable source of an alkaline urine that would predispose to calcium
phosphate stone formation.

The mean urinary pH in the seven of these twelve

patients in whom "mean urinary pH" was determined (M=6.1) was higher (p=.0Q2) than
that observed in the rest of the studied population (ju=5.3, S.D.=0.7, N=102).

There

was no significant difference (p>.05) between the TmP/GFR in these patients (^=2.9)
and the rest of the stone population (,U=3.1, S.D.=0.7, N=193). Nor was there any sig¬
nificant

difference

between

the

serum

chloride,

serum

bicarbonate,

or

lowest

recorded urinary pH of these twelve calcium phosphate stone patients and the
remainder of the stone population.
Calcium Oxalate Stones

'

It I*
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With a distribution of 151 males and 47 females in this series having oxalate
stones, it becomes clear that this type of stone disease has a predilection (p<.05) for
males (Chi Square Value>3.341).

Although oxalate stone disease is a

curse of

industrialized nations, it is the male population, especially, who suffer from the
curse.
Renal Tubular Acidosis
Of the 198 patients with calcium oxalate stones, only one was diagnosed as
having renal tubular acidosis.
Sarcoidosis
Two patients in this series had calcium oxalate stones associated with sarcoid¬
osis.

Of note was that their serum calcium averaged 10.2 mg/dL and that their

24-hour calcium excretion on the fixed diet averaged 5.2 mg/kg Wt.
Enteric Hyperoxaluria
Eight patients in the calcium oxalate—mixed calcium stone group had enteric
hyperoxaluria.

Not suprisingly, they were noteworthy for having a 24-hour urine

oxalate (JJ.=74, N=5) that was significantly (p=.G35) greater than that observed among
the other members of the stone population whose urinary oxalate values were quanti¬
fied (J-i=52, N=26). 80% of the patients in this group had a urinary oxalate of greater
than 55 mg/day. Only 27% (7 of 26) of the remaining stone patients for whom urinary
oxalate was examined had such high urinary oxalate levels.
Primary Hyperparathyroidism
The ten patients with primary hyperparathyroidism in this series included three
males and seven females.

This three to seven sexual distribution is similar to that

reported in previous studies of a large group of stone patients. (Broadus, 1981) The
serum calcium in this population was clearly above normal (JJ=11.2 mg/dL, S.D.=1.1,
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N=3).

The urinary calcium on the fixed diet (JJ=5.1 mg/kg, S.D.=1.9, N=3) was signifi¬

cantly higher (p<.001) than that observed in the remainder of the stone population
(p.=3.2 mg/kg, S.D.=1.4, N=214). 50% of the patients in this group had a fixed diet ur¬
inary calcium greater than 4,8 mg/kg of body weight.

Only 14% (31 of 214) of the

remainder of the stone population had such a degree of hypercalciuria.
"Garden-Variety Stone Disease"
Hypouresis, manifested by a urine volume of less than one liter per day, was
observed in 36 of I*!0!
patients (32%).

patients (20%).

Hyperuricosuria was manifest in 57 of 17&

(The urinary uric acid was not available in the case of one patient.)

Hypercalciuria (measured on either or both of the "free" and regulated diets) was
observed in 81 of 177 patients (45%).
From the risk factor perspective, 136 (87%) of the 156 "garden-variety" oxalate
stone patients for whom family histories were available manifested at least one of
the risk factors of positive family history (stone disease in at least one first degree
relative), hypouresis, hyperuricosuria, or hypercalciuria, with only some 13% having
no identifiable risk factors within these categories. (See Figure Five)

Of note was

the fact that positive family history for renal stone disease was seen in patients
manifesting each of the three treatable risk factors of hypouresis, hyperuricosuria,
and hypercalciuria. Of those patients for whom a family history was obtained in this
category, 12 of 23 low volume patients (43%), 22 of 42 hyperuricosurics (52%), and 32
of 69 hypercalciurics (46%) had at least one first degree relative with a history of
renal calculi. (See Figure Six)
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FIGURE 5:
Cumulative Frequency Distribution of Patients with Specific Numbers of
Identifiable Risk Factors (Positive Family History, Low Urine Volume,
Hyperuricc-suriai Hypercalciuria) among 156 Patients with "Garden-Variety" Calcium
Oxalate and Mixed Oxalate Stones
y-axis: number of patients
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FIGURE 6:
Positive Family History Manifested among Patients with Treatable Risk Factors
for Renal Stone Disease
y-axis: per cent of patients with indicated risk factor who have positive family
histories

Low Volume
43%

Hypercalciuria Hyperuricosuria
46%

52%

Looking at treatable risk factors alone (i.e. hypouresis, hyperuricosuria, and
hypercalciuria), of the 179 patients with "garden-variety" stone diseasej 44 had no
identifiable risk factors, 93 (55%) had one identifiable risk factor, 35 (20%) had two
identifiable risk factors, and 2 (1%) were positive for all three risk factors.

There

was no correlation (p>.Q5) between the number of identifiable risk factors that the
patients manifested and the mean number of renal stone episodes that they experi¬
enced per year.
Among the 36 patients with a low urine volume, the average age of presentation
at the stone clinic was 32. 26 (72%) were males and 10 (28%) were females. 6 (17%) of
the 36 had coincident hyperuricosuria, and 6 (17%) had coincident hypercalciuria.
To understand the nature of hyperuricosuria seen in stone patients, hyperuricosurics from the "garden-variety" stone population were analyzed as a separate
group. This group was made up of 52 males and 5 females. 26 (46%) were hyperuricemic
(as defined by a serum uric acid value greater than 7.0 mg/dL in a male or greater
than 6.0 mg/dL in a female). (Wyngaarden, 1976) The fractional excretion of Uric Acid
(F.E.U.A.) (j-i=.076) among this group was not significantly greater (p=.109) than the
value observed in the remainder of the stone population in whom fractional excretion
was determined (4=.063, S.D.=.031, N=23).

Serum uric acid (,U=6.8 mg/dL) was higher

(p=.001) in this group of patients than in all other patients that were studied (]J.=6.0
mg/dL, S.D.=1.7, N=17Q). 63% of this group had a serum uric acid level greater than
6.2 mg/dL, while only 42% (72 of 170) of the remaining patients had such a high level.
Dietary purine intake was also higher (p=.003) in this group of patients (j->.=156 mg)
than in all of the other stone patients studied (JJ=114 mg, S.D.=30, N=161). 55% of this
group had a dietary purine intake greater than 128 mg/day, while only 35% (56 of 161)
had such a high intake. Of note is the fact that among the entire stone clinic papula-
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tion, a positive correlation existed between Dietary Purine/kg Wt and Urinary Uric
Acid/kg Wt, (N=221, r=.186, p=.006).
To examine the nature of the hypercalciuria in the patients who were hypercalciuric on one or both diets, the 31 oxalate stone patients from the entire stone
population who fulfilled these criteria were examined as one group.
cluded

patients

with

primary

hyperparathyroidism,

sarcoidosis, and enteric hyperoxaluria.

renal

This group ex¬

tubular

acidosis,

56 of these 31 (63%) were found to have ab¬

sorptive hypercalciuria, 14 (17%) had normal calcium tolerance tests, and 11 (12%)
were not fully evaluated, as noted in the following table:

HYPERCALCIURIC?

FREE DIET only

FIXED DIET only BOTH DIETS

TOTAL

Absorptive Hypercalciuria

5

22

29

56

Normal Calcium Tol. Test

4

7

3

14

No Work-Up

5

0

6

11

14

23

38

31

TOTAL

There was no significant difference (p>.05) between the TmP/GFR of the absorp¬
tive hypercalciurics (H=3.1) and that of the non-hypercalciurics seen in the stone
clinic (p=3.0, S.D.=0.7, N=37).

Of note, there was a strong correlation (p<.001) be¬

tween the daily phosphorous intake per kg of body weight and the daily urinary
phosphorous per kg of body weight output (r=.274). (See Figure Seven)

In addition,

there was a strong correlation (p<.001) among the entire stone population between
serum phosphate and TmP/GFR (r=.656).

Excluding two patients in the series with

creatinine levels greater than 1.5, the correlation remains strong (p<.001) and the r

value for the serum phosphate vs TmP/GFR correlation increases to .760. (See Figure
Eight)

FIGURE 7;
Linear Regression Superimposed upon Scatterplot of Dietary Phosphorus vs.
Urinary Phosphorus
x-axis: dietary phosphorus (mg/kg Wt/day)...y-axis: urinary phosphorus (mg/kg
Wt/day)
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FIGURE 3:
Linear Regression Super imposed upon Scatterplot of Serum Phosphate vs.
TmP/GFR
x-axis: serum phosphate (mg/dl)...y-axis: tmp/gfr
Two patients with serum creatinine greater than 1.5 mg/dl are excluded from below
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To examine the possibility that some patients were sensitive to dietary factors
that might have promoted hypercalciuria, a subgroup of patients was examined in
particular. The 23 patients who comprised this group uiere those hypercalciuric oxal¬
ate stone patients who did not have a primary stone-predisposing process, and who
met at least one of the following conditions: 1) their urine calcium excretion on the
free diet was over 50 mg higher than on the fixed intake diet (N=21), or 2) they were
hypercalciuric on both diets, but a calcium tolerance test did not show evidence of
absorptive hypercalciuria <N=3).

The striking average decrease in calcium excretion

in going from a low-normal calcium "free" diet to a high-normal 1000—mg defined diet
may be easily appreciated in visual terms. (See Figure Nine)

FIGURE 9:
Urinary Calcium on a Low-Normal Calcium Diet vs. a High-Normal Calcium Diet in
a Population of "Dietary Hypercalciurics"
x-axis: low-normal diet on It, high-normal on rt...y-axis: urinary calcium (mg/day)
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In this group, there was no correlation between dietary oxalatej phosphorus!
purinei or protein intake (p>.05) and urinary calcium excretion. Dietary sodium intake
per kilogram body weight> howeverj was found to correlate (r=.576! p=.0045 N=23) with
urine calcium excretion per kilogram body weight on the "free" diet. (See Figure Ten)

FIGURE 10:
Linear Regression Superimposed upon Scatterplot of Dietary Sodium vs. Urinary
Calcium on Low-Normal Calcium Diet
x-axis: dietary sodium (mg/kg weight/day)■..y-axis: urinary calcium on "free
diet" (mg/kg weight/day)
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Urinary sodium excretion also correlated (r=.570? p=.009) with free diet urine
calcium for the twenty patients among the twenty-three for whom a 24-hour urine
sodium level was available. (See Figure Eleven)

FIGURE 11:
Linear Regression Superimposed upon Scatterplot of Urinary Sodium vs. Urinary
Calcium on Low-Normal Calcium Diet
x-axis: urinary sodium (mg/day)...y-axis: urinary calcium on "free diet" (mg/day)
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Finally, dietary calcium intake per kilogram body weight in these twenty-three
patients was also found to correlate (r=.471 ,p=.023) with urine calcium excretion per
kilogram body

weight on the "free" diet, (See Figure Twelve)

Of note, in this

population of "dietary hypercalciurics" the good correlation between sodium (intake
and output) and urinary calcium on the "free" diet was stronger than that between
calcium intake and urinary calcium.

FIGURE 12:
Linear Regression Superimposed upon Scatterplot of Dietary Calcium vs. Urinary
Calcium on Low-Normal Calcium Diet
x-axis: dietary calcium (mg/kg Wt/day)...y-axis: urinary calcium on "free diet"
(mg/kg Wt/day)
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DISCUSSION
There are clear limits to the usefulness of the data presented in this study.
Because the renal stone clinic operates as a referral center? the population that it
serves is likely to be somewhat skewed from the "average" population of stone pa¬
tients.

As such, the patients who became part of its data base were more likely to

represent, on the average, apparently greater degrees of stone pathology than
patients treated solely by their primary physician.
Cystine Stones
Treatment of cystinuria and prevention of cystine calculi formation centers on
monitoring the cystine excretion rate.

Since in cystine stone patients that rate is

generally higher than the maximum solubility of cytine (300 mg/L) at physiological pH,
a primary mode of therapy is reduction of the cystine concentration in urine to below
the 300 mg/L level.

A tolerable first-line approach would be forced hydration. If

water alone is insufficient, then alkalinization of the urine may be attempted, as
alkalinization of the urine to a pH of greater than 7.5 can double cystine solubility.
A concern, of course, with alkalinization is that precipitation of calcium phosphate
stones may be enhanced. Patients for whom these conservative measures are not ful¬
ly

effective

may

also

be

placed

upon

a

cystine

solubilizing

drug

such

as

D-Penicillamine. (Dahlberg, 1977) Unfortunately, this agent is quite toxic.
MAP Stones
Urease produces the physico-chemical conditiuns necessary for urine super¬
saturation with magnesium ammonium phosphate and the vast majority of Proteus iso¬
lates are urease-positive.

In this series, as in previous ones, the occurrence of

Proteus species as the primary organism associated with the magnesium ammonium
phosphate stone has obtained.
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An important point to be noted is that the majority of stone patients with mag¬
nesium ammonium phosphate stones present with a urine culture colony count of less
than IOOjOOO per milliliter. Examples of such low levels of organism counts have been
reported previously out of the Mayo Clinic series. (Smith, 1976) Consequently, dismis¬
sal of a "negative" culture may cause a hasty clinician to ignore this potentially
treatable and sometimes morbid form of renal stone disease.

Because these stones

may form secondarily to stasis or a "foreign body" focus caused by other stone
types, an always essential first-step is to screen the patient for other risk factors
and to treat those appropriately.
pletely

removed or

passed,

it

Unfortunately, unless MAP stone material is com¬
can serve as

a

nidus for

stone

recrudescence.

Therefore, successful surgical therapy requires the complete removal of all stone
material. Such procedures are often difficult and only partially successful. (Griffith,
1973)

Other treatment regimes via diet or medication are still either experimental,

impractical, or unavailable. (Broadus, 1981)
Uric Acid Stones
Because this group of patients had a highly significant (P=.0G3) lower urine vol¬
ume than the rest of the stone population, weight is added to the hypothesis of some
investigators that hypouresis is an independent risk factor for the formation of uric
acid calculi specifically.

What has not been explained is why uric acid stone

formation should be especially sensitive to urine volume. (Broadus, 1981) The import¬
ance of hyperuricosuria as a risk factor was confirmed likewise.

No evidence was

found for differing fractional excretion of uric acid levels contributing to the forma¬
tion of this type of stone. Because the average urine uric acid was 656 mg/L and uric
acid solubility varies from about 100 mg/L at pH=5 to about 1500 mg/L at pH=7, the
critical role that urinary pH can play in the formation of uric acid stones is evident.

48-

-

In an acid urine, the stone patient would be much more likely to precipate his urinary
uric acid than he would be in an alkaline urine. (Broadus, 1381) That one of the pa¬
tients in this subgroup (17%) had Crohn's disease is meaningless in itself, but it does
point out the increased association between inflammatory bowel disease and uric
acid stone formation. (Broadus, 1381)
With the population of uric acid stone formers tending to underproduce urine
chronically, forced hydration would seem to be the first step in rational treatment.
For patients producing a persistently acid urine, alkalinization with sodium bicarbon¬
ate may also be attempted, although patient compliance is often poor. (Broadus,
1381) In patients with marked hyperuricosuria, or a severe history of stone disease,
allopurinol has become the drug of choice in many uric acid stone patients.

An ana¬

logue of hypoxanthine, it is a competitive inhibitor of xanthine oxidase, decreasing
uric acid overproduction and excretion. (Holmes, 1380)
Calcium Phosphate Stones
As demonstrated by this study, an alkaline urine can be an important variable in
the pathogenesis of calcium phosphate stones. That the difference in urine alkalinity
holds up even when an obvious source of an alkaline urine factored out suggests the
importance of the association of an alkaline urine and "idiopathic" calcium phos¬
phate stones.

Patients with complete distal renal tubular acidosis are treated with

alkali in sufficient quantities so as to increase to normal their serum bicarbonate
concentration. (Broadus, 1381) When alkali abuse resulting in a "milk-alkali" syndrome
or an acetazolamide induced secondary renal tubular acidosis is suspected, then it
would seem appropriate to withdraw these medications from a patient's treatment
regimen.

If other risk factors for stone disease (e.g hypouresis, hypercalciuria) are

also present, these, too, should be investigated and, it would seem, be treated
appropriately.
Calcium Oxalate Stones
As suggested above, rational approaches to the understanding of
garden-variety calcium stones might benefit from understanding the underlying type
of stone disease that the patient has. An initial determination would be whether the
calcium oxalate stone is a secondary manifestation of a primary disease such as pri¬
mary hyperparathyroidism, distal renal tubular acidosis, enteric hyperoxaluria, or
sarcoidosis. Presumably, treatment of the underlying disease would head off the for¬
mation of stones.

Once a primary disease has been ruled out, the risk factor

approach can prove most useful.
stone

disease

could

be

In this series, a risk factor for calcium oxalate

identified

garden-variety type of stone.

in over

three-fourths of

patients

with

the

With low urine volumes, hypercalciuria, and hyper¬

uricosuria all being potentially modifiable, theoretical understanding of risk factors
might be usefully applied to reducing risk of recurrent stone formation. Patients pro¬
ducing a urine volume of below one liter per day might be instructed to increase their
water intake regularly.

Dietary modifications may also be made. Unnecessary phar¬

macologic doses of Vitamin C should be eliminated from the patient's intake. (Smith,
1973)

Because it is metabolized to oxalic acid, the removal of excess Vitamin C can

lead to a significant decrease in oxalate excretion through the urine.
For the risk factor of hyperuricosuria associated with calcium oxalate stones,
several important points may be made.

The fractional excretion of uric acid is no

greater in the "garden-variety" stone-formers with hyperuricosuria than in the re¬
mainder of the stone population.

Nevertheless, their level of serum uric acid and

their average level of purine intake is higher than that of the remainder of the stone
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population. In addition, the correlation between dietary purine/kg Wt and urinary uric
acid/kg Wt is highly significant for the entire stone population Cp=.Q06).

Taken

together, these facts suggest (but, of course, do not prove) that the hyperuricosuria
seen in the calcium oxalate stone population is not caused by a defect in the excre¬
tion of uric acid, but rather reflects purine gluttony.

Although treatment modalities

were beyond the scope of this study, if this hypothesis were true, it would provide a
rational explanation for the so-called "Western diet" acting to predispose patients
to renal calculi.

Presumably, if this hypothesis were true, hyperuricosuric calcium

oxalate stone formers might be able to reduce the degree of or eliminate one of their
risk factors for stones by modifying their dietary intake of purines.

In practice,

most such patients are treated with allopurinol.
The pathophysiological mechanisms responsible for "idiopathic" hypercalciuria
are controversial. In the present series, the majority of hypercalciuric patients dis¬
played evidence of the specific syndrome of so-called absorptive hypercalciuria.

As

an extension of the present series, these patients were evaluated in detail, and an
increase in circulating l,25-(OH)^D, the hormonal form of vitamin D responsible for
<L

the regulation of intestinal calcium transport, was observed in eighty per cent of
patients. (Broadus, 1984)

The "phosphate-leak" hypothesis is a recent proposal put

forth to explain this constellation of findings. In essence, this hypothesis holds that
the primary abnormality in affected patients is a proximal tubular "leak" of phos¬
phate, leading to secondary stimulation of

l,25-(0H)oD synthesis (known to be

sensitive to hypophosphatemia) and the remaining features of the syndrome.

The

findings of this series do not support this hypothesis, in that a tendency toward a
reduction in TmP/GFR and hypophosphatemia was found in both hypercalciuric and
non-hypercalciuric patients, indicating that hypophosphatemia could not regularly
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and/or statistically be related to circulating l,25-(0H)oD or, in fact, even hypercalciuria, in patients with calcium oxalate stone disease. (Broadus, 1334) Although this
point is controversial (Tschope, 1380), the findings in this series in this regard are
in agreement with the only other large series in which this question was examined
systematically. (Edwards, 1365)

Based on these and other observations in patients

with this syndrome, an alternate pathogenetic theory has been proposed. (Broadus,
1384)
There is no consensus regarding optimal medical therapy for the treatment of
this form of hypercalciuria. (Broadus, 1381)

Diet may be approached through an in¬

creased fluid and a decreased (about 400 mg/day) calcium intake. It is possible that
a restriction in calcium intake may be physiologically compensated for by an in¬
creased

oxalate

absorption

and

excretion—so

reducing calcium intake alone. (Broadus, 1331)

negating

potential

benefits

of

Sodium cellulose phosphate, which is

nonabsorbable and can complex with calcium, has been reported to be effective in
reducing calcium excretion in patients with absorptive hypercalciuria. (Pak, 1374) If
all other approaches fail, therapy may also be instituted empirically. Thiazides have
been reported highly effective in moderating undifferentiated hyperoxaluria and hy¬
percalciuria, and oral phosphorus has been reported to increase the excretion of
pyrophosphate, an inhibitor of stone formation and growth. (Yendt, 1378, Thomas,
1378, Pak, 1373)
The identification of a subpopulation of "dietary hypercalciurics" is an extreme¬
ly important component if one wishes to appreciate the nature of hypercalciuria.

In

this series "dietary hypercalciurics" were defined among the garden-variety calcium
oxalate stone population as being those hypercalciuric patients whose 24 hour calci¬
um excretion on a free diet was at least 50 mg than their calcium excretion on a

fixed 1000-mg calcium diet or who met the condition that they be hypercalciuric on
both the fixed and free diets* yet have a normal response to a calcium tolerance
test.

This population excretes an especially high level of calcium on a diet that on

the basis of its calcium content alone should not predispose to hypercalciuria. If the
statistical association between dietary sodium intake and urinary calcium excretion
on a free intake diet that was established in this group bears out in physiological
terms* then it would seem that their hypercalciuria might partially result from die¬
tary factors.

In particular, a high sodium diet would tend to predispose patients in

this subpopulation to hypercalciuria and, presumably, renal calculi.

If the converse

of this hypothesis is true, then a restricted sodium diet in this group of patients
might reduce urine calcium excretion and, presumably, decrease a patient's chances
of developing renal calculi.
Possibly, by eliminating as many risk factors as possible, calcium oxalate stone
disease, indeed, most renal stones, might largely be prevented.
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APPENDIX ONE—NUMERICAL DATA
All Patients:

Category

Number

Mean

Std Dev

Age at First Episode (yrs)

226

34

12

Frequency of Episodes (#/yr)

217

2

4

Serum Calcium (mg/di)

223

3.6

0.6

Serum Uric Acid (rng/dl)

227

6.2

1.7

Serum Phosphate (mg/dl)

223

3.2

0.5

Serum Carbon Dioxide (mEq/L)

228

26.1

3.1

Serum Chloride (mEq/L)

228

104

3

Dietary Calcium (mg/day)

217

563

330

Dietary Calcium (mg/kg Wt/day)

217

Dietary Oxalate (mg/day)

217

Dietary Oxalate (mg/kg Wt/day)

217

Dietary Liquid (ml/day)

135

2014

342

Dietary Liquid (ml/kg Wt/day)

135

28

13

Dietary Purine (mg/day)

217

123

34

Dietary Purine (mg/kg Wt/day)

217

Dietary Protein (g/day)

217

Dietary Protein (g/kg Wt/day)

217

Dietary Sodium (mg/day)

217

Dietary Sodium (mg/kg Wt/day)

217

Dietary Phosphorus (mg/day)

216

Dietary Phosphorus (mg/kg Wt/day)

216

7.7
47
0.67

1.7
83
1.20
2175
23.4
1225
16.5

4.7
51
0.37

1.3
35
0.43
1215
18.1
516
6.3

Urine Volume (ml/day)

229

1607

803

"Free" Urine Calcium (mg/day)

227

229

117

"Free" Urine Calcium (mg/kg Wt/day)

227

"Fixed" Urine Calcium (mg/day)

222

"Fixed" Urine Calcium (mg/kg Wt/day) 222

3.05
243
3.30

1.51
114
1.50

Urine Sodium (mEq/day)

113

Urine Sodium (mEq/kg Wt/day)

113

1.95

0.85

33

0.063

0.03:

Fractional Excretion of Uric Acid
Urine Uric Acid (mg/day)

223

Urine Uric Acid (mg/kg Wt/day)

223

Urine Oxalate (mg/day)

31

Urine Oxalate (mg/kg Wt/day)

31

150

669
3.33
55
0.75

73

251
3.08
38
0.54

Urine Phosphorus (mg/day)

222

Urine Phosphorus (mg/kg Wt/day)

222

12.7

4.7

Low Urine pH

223

5.3

0.6

Mean Urine pH

109

5.8

0.7

TmP/GFR

203

3.1

0.7

Urine Culture (Organisms/ml)

203

959

11300

401

74000

Magnesium Ammonium Phosphate Stone Patients:

Category
Urine Volume (ml/day)

Number
9

Mean
1771

Std Dev
334

Free" Urine Calcium (mg/day)

9

196

115

"Free" Urine Calcium (mg/kg Wt/day)

9

"Fixed" Urine Calcium (mg/day)

9

"Fixed" Urine Calcium (mg/kg Wt/day)

9

Urine Uric Acid (mg/day)

9

611

272

Urine Phosphorus (mg/day)

9

1029

573

TmP/GFR

9

Urine Culture (Organisms/ml)

S

2.3
190
2.5

2.4
45600

1.7
173
1.3

0.6
47300

Uric Acid Stone Patients:

Category

Number

Mean

Std Dev

Serum Calcium (mg/dl)

6

9.7

0.4

Serum Uric Acid (mg/dl)

6

7.0

2.0

Urine Volume (ml/day)

6

1000

378

"Free" Urine Calcium (mg/day)

6

157

67

"Free" Urine Calcium (mg/kg Wt/day)

6

"Fixed" Urine Calcium (mg/day)

6

"Fixed" Urine Calcium (mg/kg Wt/day)

6

3.0

Fractional Excretion of Uric Acid

2

0.035

Urine Uric Acid (mg/day)

6

TmP/GFR

6

2.0
239

656
3.0

0.8
124
1.7

321
0.6
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Cystine Stone Patients:

Category

Number

Mean

0.4

Serum Calcium (rng/dl)

3

Urine Volume (ml/day)

3

1160

299

"Free" Urine Calcium (mg/day)

3

156

125

"Free" Urine Calcium (mg/kg Wt/day)

3

Urine Cystine (mg/day)

3

811

564

Urine Uric Acid (mg/day)

3

378

649

TmP/GFR

O
i-

9.6

Std Dev

1.9

1.5

3.9

Calcium Phosphate Stone Patients:

Category

Number

Mean

Std De

Serum Calcium (mg/dl)

17

9.5

0.4

Serum Carbon Dioxide (mEq/L)

17

25.2

3.0

Urine Volume (ml/day)

17

1361

513

"Free" Urine Calcium (mg/day)

17

242

141

"Free" Urine Calcium (mg/kg Wt/day)

17

"Fixed" Urine Calcium (mg/day)

17

"Fixed" Urine Calcium (mg/kg Wt/day)

17

3.3
231
3.3

1.8
104
1.4

Mean Urine pH

11

6.0

Urine Uric Acid (mg/day)

17

602

205

Urine Phosphorus (mg/day)

17

878

280

T mP/GFR

14

2.8

0.3

0.3

Calcium Phosphate Stone Patients without RTAj or a History of Antacid Abi
Acetazolarnide Ingestion:

Category
Urine Volume (ml/day)
Mean Urine pH

Number
12
7

Mean
1337
6.1
248

Std Dev
548
0.2

"Free" Urine Calcium (mg/day)

12

"Free" Urine Calcium (mg/kg Wt/day)

12

"Fixed" Urine Calcium (mg/day)

12

"Fixed" Urine Calcium (mg/day)

12

Urine Uric Acid (mg/day)

12

613

115

Urine Phosphorus (mg/day)

12

863

240

TmP/GFR

10

Calcium Oxalate Stone Patients with Sarcoidosis:

3.4
282
3.9

2.9

145
1.9
115
1.6

0.9

Category

Number

Mean

Serum Calcium (mg/dl)

2

10.2

Serum Uric Acid (mg/dl)

2

8.4

Serum Phosphate (mg/dl)

2

3.2

Urine Volume (ml/day)

2

Std Dev

1750
188

"Free" Urine Calcium (mg/day)
"Free" Urine Calcium (mg/kg Wt/day)

O

"Fixed" Urine Calcium (mg/day)

V
i-

2.78
365

"Fixed" Urine Calcium (mg/kg Wt/day)

2

Urine Uric Acid (mg/day)

2

632

Urine Phosphorus (mg/day)

2

1240

5.17

Calcium Oxalate Stone Patients with Enteric Hyperoxaluria:

Category

Number

Mean
9.3

Std Dev

Serum Calcium (mg/dl)

8

Urine Volume (ml/day)

8

1231

316

"Free" Urine Calcium (mg/day)

8

147

71

"Free" Urine Calcium (mg/kg Wt/day)

8

"Fixed" Urine Calcium (mg/day)

8

"Fixed" Urine Calcium (mg/kg Wt/day)

8

Urine Uric Acid (mg/day)

8

Urine Uric Acid (mg/kg Wt/day)

8

2.1
119
1.7
514
7.14

0.5

1.1
26
0.5
126
2.24

Urine Phosphorus (mg/day)

8

703

Urine Phosphorus (mg/kg Wt/day)

8

Urine Oxalate (mg/day)

5

Urine Oxalate (mg/kg Wt/day)

5

1.0

0.3

TmP/GFR

8

3.2

0.87

280

9.98

5.01

74

19

Calcium Oxalate Stone Patients with Primary Hyperparathyroidism:

Category

Number

Mean

Std Dev

1.1

Serum Calcium Cmg/dl)

9

Urine Volume (ml/day)

9

1577

571

"Free" Urine Calcium (mg/day)

10

326

154

"Free" Urine Calcium (mg/kg Wt/day)

10

"Fixed" Urine Calcium (mg/day)

8

"Fixed" Urine Calcium (mg/kg Wt/day)

8

11.2

;.9
396

1.3
I

1.9

10

714

'68

Urine Phosphorus (mg/day)

9

1102

563

TmP/GFR

7

Urine Uric Acid (mg/day)

Garden-Variety Calcium Oxalate Stones:

2.7

0.7
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Category

Number

Mean

Std Dev

Serum Calcium (mg/dl)

179

Urine Volume (ml/day)

179

1644

844

"Free" Urine Calcium (mg/day)

178

233

111

"Free" Urine Calcium (mg/kg Wt/day)

178

"Fixed" Urine Calcium (mg/day)

177

9.6

3.1
251

"Fixed" Urine Calcium (mg/kg Wt/day) 177
Urine Uric Acid (mg/day)

178

Urine Uric Acid (mg/kg Wt/day)

178

Urine Phosphorus (mg/day)

173

Urine Phosphorus (mg/kg Wt/day)

173

Urine Oxalate (mg/day)

31

Urine Oxalate (mg/kg Wt/day)

31

TmP/GFR

3.3
679
8.9
933
12.8
40

160

0.5

1.4
105
1.4
242
3.0
401
4.6
43

0.53

0.60

3.1

0.7

Calcium Oxalate Stone Patients with Low Urine Volume:

Number

Mean

Age at First Stone Event (Years)

36

32

10

Urine Volume (ml/day)

36

1022

338

"Free" Urine Calcium (mg/day)

36

166

71

"Free" Urine Calcium (mg/kg Wt/day)

36

"Fixed" Urine Calcium (mg/day)

35

Category

2.32
189

Std Dev

0.97
62

"Fixed" Urine Calcium (mg/kg Wt/day)

35

Urine Uric Acid (mg/day)

36

Urine Uric Acid (mg/kg Wt/day)

36

Urine Phosphorus (mg/day)

34

Urine Phosphorus (mg/kg Wt/day)

34

2.67
578
3.16
366
12.1

0.39
215
3.35
428
5.6

Calcium Oxalate Stone Patients with Hyperuricos uria:

Category

Number

Mean

Std Dev

Serum Calcium (mg/dl)

57

9.6

0.4

Serum Uric Acid (mg/dl)

57

6.3

1.6

Dietary Purine (mg/kg Wt/day)

56

1.3

1.4

Dietary Purine (mg/day)

56

156

104

Urine Volume (ml/day)

57

2030

1112

Urine Uric Acid (mg/day)

57

956

152

Fractional Excretion of Uric Acid

16

Urine Phosphorus

57

1246

458

"Free" Urine Calcium (mg/day)

57

267

123

"Fixed" Urine Calcium (mg/day)

57

261

113

0.076

Calcium Oxalate Stone Patients with Absorptive Hypercalciuria:

0.034
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Category

Number

Mean

Std Dev

Serum Phosphate (mg/dl)

56

Urine Volume (ml/day)

56

1780

794

"Free" Urine Calcium (mg/day)

56

308

97

"Fixed" Urine Calcium <mg/day)

56

331

81

Urine Uric Acid (mg/day)

56

675

219

Urine Phosphorus (mg/day)

56

1018

397

TmP/GFR

56

3.1

3.1

0.5

0.7

Calcium Oxalate Stone Patients with Dietary Hy percalciuria:

Category

Number

Mean

Std Dev

Urine Volume (ml/day)

23

1962

937

"Free" Urine Calcium (mg/day)

23

394

89

"Fixed" Urine Calcium (mg/day)

23

285

80

Urine Uric Acid (mg/day)

23

800

250

Urine Phosphorus (mg/day)

23

1191

376

TmP/GFR

20

3.0

0.8

APPENDIX TWO—METHODS AND FORMS

Initial contact with patients occurred by telephone. On this important occasion
the patients were instructed as to what to expect in the evaluation of his stone dis¬
ease.

They were told that they would be sent a 24-hour urine specimen container,

which they were to bring with them to their first clinic appointment.

They were also

sent the "Diet History Instruction Form" (see following page) which told them how to
record their dietary intake.

Finally, they were instructed to arrive at his first renal

stone clinic visit in a state of fasting, so that the initial screening tests of blood
and urine were on standardized samples.
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DIET HISTORY INSTRUCTION FORM

co r o

1.

4.

5.

You are to write down everything you eat and drink for a period of three days
that you consider to be representative of what you usually eat, with attention
to the following:
a. The three days do not need to be consecutive.
b. One of the days you keep a record of what you eat and drink should be the
same day you do a 24 hour collection of urine (please specify this day clearly in
your booklet).
Use this booklet to keep a record of your food intake.
Include the complete amounts you eat and what time you eat.
Estimate the portion size of all foods and list measures for all items. For
example, an average size chicken leg is about 3 oz. of meat, while 1 slice of cold
cuts is about 1 oz. of meat. All beverages, canned fruits, vegetables and cereals
should be measured with a measuring cup, not a coffee cup.
Be sure to include butter, margarine or fat if used with vegetables or bread!
gravies or sauces? condiments such as mustard, catsup, mayonnaise or salad
dressings! and milk, cream or sugar used in coffee or tea and on cereal.
Here is an example:

6.

7:00 A.M.

Vi
1
2
1

10:00 A.M.

1 cup coffee with 2 tablespoons
2 teaspoons of sugar
1 sweet roll with 1 pat margarine

12:00 Noon

1 large fried hamburger
Vi cup mashed potatoes with 2 tablespoons gravy
Vi cup peas with 1 teaspoon of margarine
1 glass (8 oz.) milk
Vi cup fruit cocktail
2 chocolate filled cookies

3:15 P.M.

Mounds candy bar

grapefruit with 2 teaspoons of sugar
egg
strips bacon
toast with 1 teaspoon butter
of evaporated milk

and

If you encounter any problems or have questions concerning your recall, please
call during Tuesday morning clinic hours and ask to speak to the dietitian
regarding your diet. The phone number is (203)-43S-8060.
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On arrival at the renal stone clinic, the patient is given a copy of the form
reproduced below:

"FIRST RENAL STONE CLINIC VISIT"

Your first Renal Stone Clinic visit is designed to obtain:
a) A clinical history and physical examination by the physician.
b) A detailed dietary history obtained by the nutritionist.
c) Initial screening tests of blood and urine.
d) The initiation of a search for a history of kidney stones in your family.

In

addition,

your

initial visit is designed to allow for

further diagnostic

laboratory testing under optimum conditions. This testing includes:
a) Collection of two 24-hour urine specimens while you are eating a defined 1000
mg calcium diet.
b) Many patients will have an x-ray examination (either plain x-rays of the
kidneys or an intravenous pyelogram).

If you are to have any type of kidney x-ray,

you will be given a packet of material concerning preparation for this x-ray. Please
note that this preparation would interfere with the 24-hour urine collections, so that
in no case should a 24-hour specimen of urine be collected during preparation for
x-rays.

For patients living in the metropolitan New Haven area, the x-rays will be

scheduled at a time several or more days distant from the urine collections.

For

patients coming from a longer distance, the 24-hour specimens may be collected and
refrigerated for a day during which time the preparation for x-rays is taking place
(in this case begin the x-ray preparation the day before the scheduled x-ray rather
than following the two day instructions included in the packet).
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RENAL STONE CLINIC H & P FORM

I.

Name:
Address:
Telephone number:
Age:
Sex:

II.

Referring physician:
Address:
Telephone number:

III.

Clinical stone events. Specify date, side, and type (passed, removed, historical
event, or radiologic new stone) of each event.
Total number_Stones per patient year_Bilateral?_

IV.

Previous evaluation:
a. Stone analysis (% composition, laboratory name):
b. Chemistries:
c. C & S and pH:
d. IVP:
e. Date and findings on last x-ray:

V.

Prior treatment. Specify when instituted, estimate of compliance, and estimate
of benefit.
a. Forced fluids:
b. Diet:
c. Medication:
d. Present or recent medications (when discontinued):

VI.

Past history:
a. Childhood illnesses:
b. Adult illnesses:
c. Hospitalizations:
d. Operations:
e. Allergies:

VII. Clinical and social history.
a. Abnormal serum or urinary calcium:
b. Abnormal serum or urinary uric acid:
c. Hyperparathyroidism:
d. Gout:
e. Ulcer disease (dyspepsia):
f. Antacid intake:
g. Analgesic intake:
h. Vitamin intake:
i. Chronic diarrhea:
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j. Hypertension:
k. Kidney or bladder infection:
l. Osteoporosis, bone pain, fractures:
•ffi. Sun exposure:
n. Periods of dehydration:
o. Work:
P. Smoking:
q. Ethanol:
Comments and/or Review of Systems:
VIII. Dietary summary:
IX.

Family history summary:

X.

Physical examination:
1. HEENT:
2. Chest:
3. Abdomen:
4. Genitalia:
5. Extremities:
6. Neurologic:

XI.

Summary:
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At the conclusion of the first stone clinic appointment, the patient is given a
detailed instruction form explaining the procedure for collecting a 24-hour urine on a
defined 1000 mg calcium intake:

"INSTRUCTIONS FOR TWO 24-HOUR URINE COLLECTIONS ON A 1 000 MG CALCIUM
INTAKE"

1. These collections are ideally performed on the weekend following your first
Renal Stone Clinic visit, and the detailed instructions below assume that you intend
to collect

these specimens

on the weekend.

Any

equivalent

period of

time is

satisfactory, and you may modify the instructions below for your own convenience.

2. Friday morning (1 day before beginning the urine collections) begin eating the
diet on which you were instructed by the nutritionist. Also begin to take the calcium
gluconate tablets, two tablets with each meal (6 tablets per day).

Please note that

these tablets are large and should be chewed to a fine powder before swallowing.
Continue the diet and the calcium tablets on Saturday and Sunday, the two days of
urine collections.

3. Estimate what time you will get

up

on the following Monday morning, and write

this time in the three blanks below.

SATURDAY
4. _a.m.: Void into the toilet as usual. (You may go back to bed after voiding).
The next time you void, collect the urine into a clean container and pour it carefully
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in to one of the collection jugs.

The collection jugs contain an acid preservative, so

that you should not void directly into them.

Continue to collect all urine passed!

refrigerate the collection bottle during and after completion of the collection.

SUNDAY
5. _a.m.: Void and add this urine to the same bottle you were using on
Saturday! this completes the first 24-hour specimen. The next time you void, pour the
urine into a new collection jug.

Continue to collect all urine passed, and refrigerate

the specimen.

MONDAY
6. _a.m.: Void and add this urine to the bottle you were using on Sunday! this
completes the second 24-hour specimen.

7.

Label

each

bottle

carefully

with

the

date

of

the

collection

(e.g.

3/1 7-3/18/77).

8. The collection jugs should be returned to the clinic on DANA III. Please do not
eat or drink anything before bringing the specimens to the clinic! you are scheduled
to have a blood specimen drawn on the same morning.
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FLOW DIAGRAM AND DATA BASE DERIVED FROM THE ORAL CALCIUM TOLERANCE
TEST (BROADUS, 1378, 1981)

ORAL CALCIUM TOLERANCE TEST
I. HOW DIAGRAM

CONTROL
PERIOD

II.

—r~
120
"

U)

1

1
LAG
TIME

240’
U2

EXPERIMENTAL
PERIOD

360‘
U3

QATA BASE
A

STATIC MEASUREMENTS (CONTROL PERIOD)
1

B.

BASAL SERUM CALCIUM & PHOSPHOROUS

2

FASTING CALCIUM EXCRETION

3.

FASTING TMP/GFR

4.

BASAL NEPHROGENOUS OR TOTAL cAMP EXCRETION

5.

BASAL VITAMIN 0 METABOLITES

DYNAMIC MEASUREMENTS (EXPERIMENTAL VS CONTROL PERIOD),
1

CALCEHIC RESPONSE AS INDEX OF “CALCIUM TOLERANCE"

2.

CALCIUR1C RESPONSE (a mg CALCIUM/IOO ML GF) AS INDEX OF G! AbSORPTION

3.

SUPPRESSIBILITT OF NEPHROGENOUS OR TOTAL cAMP EXCRETION
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Patients were prepared for the calcium tolerance test test by following a res¬
tricted (about 400 mg/day) calcium diet for ten days prior to testing and by fasting
except for distilled water beginning at 8 p.m. the night before the test began.

Pa¬

tients were hydrated with 8 ounces of distilled water semi-hourly, beginning at 7 a.m.
and continuing through the completion of the test. At 7 a.m., the urine was voided and
discarded. At 8 a.m., a serum calcium specimen was obtained. At 9 a.m. a urine speci¬
men was obtained.

An oral dose of approximately one gram of elemental calcium

(administered as 35 ml of calcium glubionate syrup plus 8 ounces of lactase-treated
milk) was administered at 9 a.m., immediately following the first urine collection. At
11 a.m. a urine sample was collected and discarded. At 12 noon, another serum sample
was obtained. The test finally concluded with a last urine collection at 1 p.m.. Except
for voiding, the patients remained inactive betwee 8 a.m. and 1 p.m. on the test day.
The three collection periods represented a fasting control period, a two-hour lag
period in which peak calcium absorption could occur, and an experimental period that
demonstrated the maximal systemic affects of the absorbed calcium.

The calciuric

response was calculated by subtracting the rate of calcium excretion during the con¬
trol period from that during the experimental period.

Calcium excretion rates were

calculated by using the formula: CaE=Urine Calcium X Serum Creatinine/Urine Creati¬
nine.
GF.

The upper-normal limit for the calciuric response is 0.2 mg calcium per 100 ml
Absorptive hypercalciuria was diagnosed in patients who met the following cri¬

teria: 1) Calcium excretion rate greater than 300 mg/day and/or greater than 4
mg/kg/day on the 1000-mg calcium diet, 2) Hyperabsorption of calcium (as measured
by the calciuric response to the calcium tolerance test, and 3) normal or suppressed
parathyroid function in the fasting state (Nephrogenous cAMP less than 2.7 nmol/dL
GF). (Broadus, 1984)

Total urinary cAMP was determined with the formula: Total
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UcAMP=Urinary cAMP X Serum Creatinine/Urine Creatinine.

Nephrogenous cAMP was

determined by subtracting the plasma cAMP level (i.e. the filtered load of cAMP) from
the total amount of cAMP excreted.
Data were analyzed by means of the unpaired t-test and univariate linear
regression, all performed on the CLINFO system at the Clinical Research Center at
the Yale-New Haven Medical Center.
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